Regeneron's Covid-19 Antibody Cocktail Had 2021 U.S. Sales Near $6 Billion
10 January 2022 - 10:54PM
Dow Jones News
By Matt Grossman
Regeneron Pharmaceuticals Inc.'s antibody cocktail for treating
Covid-19 generated sales of about $5.82 billion in the U.S. in
2021, Regeneron estimated on Monday.
The Tarrytown, N.Y.-based pharmaceutical company said the
preliminary sales figure was based on unaudited fourth-quarter
sales of about $2.29 billion for the therapy. Regeneron released
the estimate ahead of its appearance at an industry conference
later Monday.
Regeneron also estimated that its Eylea injection, used to treat
age-related macular degeneration and other eye conditions,
accounted for U.S. sales of about $5.79 billion. In the fourth
quarter, Eylea sales were about $1.54 billion, Regeneron said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
January 10, 2022 06:39 ET (11:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
